Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double‐blind, placebo‐controlled randomized trial

• Published in: Journal of thrombosis and haemostasis Vol. 12; no. 4; pp. 459 - 468
• Main Authors: Kline, J. A., Nordenholz, K. E., Courtney, D. M., Kabrhel, C., Jones, A. E., Rondina, M. T., Diercks, D. B., Klinger, J. R., Hernandez, J.
• Format: Journal Article
• Language: English
• Published: England Elsevier Limited 01.04.2014
• Subjects: Adult; Aged; Double-Blind Method; Dyspnea - complications; Female; Fibrinolytic Agents - therapeutic use; Hemorrhage - complications; Humans; Male; Middle Aged; Probability; Prospective Studies; pulmonary embolism; Pulmonary Embolism - drug therapy; Pulmonary Embolism - mortality; Quality of Life; randomized controlled trial; Shock - complications; thrombolytic therapy; Tissue Plasminogen Activator - therapeutic use; Treatment Outcome; ventricular function, right; thrombolytic therapy; pulmonary embolism; quality of life; ventricular function, right; randomized controlled trial

Summary Background Acute pulmonary embolism (PE) can worsen quality of life due to persistent dyspnea or exercise intolerance. Objective Test if tenecteplase increases the probability of a favorable composite patient‐oriented outcome after submassive PE. Methods Normotensive patients with PE and rig...